Frank Jing
About Frank Jing
Frank Jing serves as the Senior Director and Head of Process Development and Product Operations at Tenaya Therapeutics, bringing extensive experience in gene therapy viral vector manufacturing. He has held various engineering roles in notable companies, including MedImmune, Genentech, and Astellas Pharma, and has a strong academic background in biotechnology and chemical engineering.
Current Role at Tenaya Therapeutics
Frank Jing serves as the Senior Director and Head of Process Development (PD) and Process Product Operations (PPO) at Tenaya Therapeutics. He has held this position since 2019, contributing to the advancement of gene therapy viral vectors aimed at curative treatments for heart diseases. His leadership in this role focuses on the development and optimization of processes that enhance the efficacy and safety of gene therapies.
Previous Experience in Process Development
Frank Jing has a robust background in process development and manufacturing within the biotechnology sector. He worked at MedImmune as a Process Development Engineer from 2005 to 2009, and later held positions at Astellas Pharma and Adverum Biotechnologies, where he managed process development and manufacturing for AAV. His experience also includes a role at Genentech as a Late Stage Process Development Engineer from 2013 to 2015, and a position at Adicet Bio, Inc. as Senior Manager for Engineered GammaDelta CAR-T from 2017 to 2019.
Educational Background
Frank Jing holds a Master of Science degree in Biotechnology with an emphasis in Regulatory Affairs from The Johns Hopkins University. He also earned both a Bachelor of Science and a Master of Science in Chemical Engineering from UCLA. His educational background provides a strong foundation for his expertise in cell and gene therapy process development.
Expertise in Gene Therapy
Frank Jing possesses extensive expertise in the field of cell and gene therapy process development. His work primarily focuses on the manufacturing of gene therapy viral vectors, which are crucial for developing innovative treatments for various diseases, particularly heart conditions. His knowledge in this area is supported by his educational qualifications and years of practical experience in the biotechnology industry.